BioSante Female Libido Drug Hype Was Fraudulent: Suit

Law360, New York (February 6, 2012, 12:09 PM EST) -- An investor hit BioSante Pharmaceuticals Inc. with a securities fraud class action Friday in Illinois claiming CEO Stephen Simes told tall tales about how an experimental women's libido drug was bound for torrid sales before clinical results threw cold water on shareholders.

By the time the Lincolnshire, Ill.-based company told investors in December that late-stage tests had shown its LibiGel drug was no better than a placebo at making women feel frisky, Simes had spent more than a year hyping the drug's prospects — and BioSante...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Lauria v. BioSante Pharmaceuticals, Inc. et al


Case Number

1:12-cv-00772

Court

Illinois Northern

Nature of Suit

850(Securities/Commodities)

Judge

Honorable Joan B. Gottschall

Date Filed

February 2, 2012

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.